Sodium Oxybate

LXB improved all measures of function and work productivity among patients with idiopathic hypersomnia, according to findings presented at the American Neurological Association Annual Meeting.

The REST-ON trial, a phase 3 study of a sodium oxybate formulation for narcolepsy, demonstrated “significant consolidation of sleep” compared with placebo as well as improvements in sleep quality and narcolepsy symptoms.

Most participants with narcolepsy with cataplexy who took the sodium oxybate therapy Xyrem at the beginning of a randomized withdrawal study transitioned to lower-sodium oxybate at the same dose or within one titration step.